1. Describe the results and significance of the ANNEXA-4 clinical trial of andexanet alfa in patients with severe bleeding due to Factor Xa inhibitors.
2. Summarize the specific approaches to emergency management of bleeding related to oral anticoagulant therapy.
3. Describe how this approach varies according to the particular oral anticoagulant, the urgency of the need for reversal, and the medical setting.
4. Describe the mechanism of action of the anticoagulant reversal agents, idarucizumab and andexanet alfa.
5. List the specific indications for the use of vitamin K, fresh frozen plasma, prothrombin complex concentrate, idarucizumab, and andexanet alfa in a patient with severe oral anticoagulant associated bleeding.

To to view this newsletter, please go to: https://www.emcreg.org/

There is no fee.

Accreditation and Designation Statement

This Activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and EMCREG-International. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclaimer Statement

The opinions expressed during this activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

No faculty are available for this activity at this time.

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.